HYDERABAD: Bharat Biotech, which is into developing Covaxin, a vaccine candidate for Covid-19, on Friday said it has successfully completed interim analysis of Phase I and II trials and is initiating Phase-III trials in 26,000 participants.
"After successful completion of the interim analysis from the Phase 1 & 2
Related News
Covaxin update: Bharat Biotech gets nod from DCGI panel for Phase III trials
Drugs Controller General of India (DCGI's) Expert Committee recommended granting permission to conduct Phase III clinical trial for Bharat Biotech's Covid-19 vaccine...
Live Mint 2020-10-22COVID-19 Vaccine Covaxin, Developed by Bharat Biotech, Cleared For Phase 3 Clinical Trials
New Delhi, October 22: Covaxin, India's first indigenously-developed vaccine candidate against coronavirus (COVID-19), has been cleared by the Drugs Controller General of...
Yahoo Daily News 2020-10-22DCGI's expert panel recommends Phase 3 clinical trial nod for Bharat Biotech's Covid-19 vaccine
The expert panel at Central Drugs Standard Control Organisation (CDSCO) has recommended the top drugs regulator to grant permission to Bharat Biotech to conduct phase III...
Mid Day 2020-10-23Bharat Biotech#39;s Covaxin receives approval for Phase III trials: Reports
The approval was reportedly given after assessing data from Phase I and II and animal challenge study. Moneycontrol News Bharat Biotech's coronavirus vaccine Covaxin has...
Moneycontrol
2020-10-22
India's vaccine maker says COVID-19 vaccine to be at least 60 pct effective
NEW DELHI, Oct. 23 (Xinhua) -- Indian vaccine maker Bharat Biotech said the COVID-19 vaccine Covaxin is likely to be at least 60 percent effective. "The benchmark for the...
Xinhua 2020-10-23Covid-19: Kerala to take part in vaccine trials
THIRUVANANTHAPURAM: Kerala has expressed its willingness to take part in the clinical trials for a vaccine for Covid-19 being conducted across the country. The state...
The Times of India 2020-10-23Cyber attack cripples Dr Reddy's global operations
HYDERABAD: Less than a week after Dr Reddy’s Laboratories got the Indian drug regulator General of India's (DCGI) approval to conduct Phase 2/3 trials of Russian Covid-19...
The Times of India 2020-10-22